Molecular profiling of microinvasive breast cancer microenvironment progression

F. Lessi1*†, C. Scatena2†, P. Aretini1, M. Menicagli1, S. Franceschi1, A. G. Naccarato2‡ and C. M. Mazzanti1‡

Abstract

Background: Tumors develop by progression through a series of stages. Every cell of the tumor microenvironment is constantly changing in the flow of the cancer progression. It has become clear in recent years that stroma is essential for tumor maintenance and growth. Here, we aimed to give a chronological order of gene expression changes given in the dynamical framework of microinvasive breast cancer microenvironment.

Methods: RNA-seq was performed on seven microinvasive breast cancers. For each of them we microdissected seven different portions of the tumor, four related to the breast epithelium and three to the stroma. Breast epithelium was chronologically subdivided in normal breast epithelium (NBE), carcinoma in situ (CIS), emerging invasive fingers (EIF) and invasive breast cancer (IBC). For each of the breast epithelium subdivisions we collected the adjacent stroma (S): S-NBE, S-EIF and S-IBC.

Results: The overall differentially expressed genes (DEGs) in all the compartments were analysed and evaluated to understand the pathways involved in tumor progression. Then we analysed the DEGs of the epithelial and stromal portions in comparison with the normal portions. We observed that the stromal cells are necessary for the development and the maintenance of the tumor, especially in tumor progression. Moreover the most important genes involved in the main metabolic pathways were analysed and the communications within the different cell compartments were highlighted.

Conclusions: As a future perspective, a deeply study of the identified key genes, particularly in the stromal cells, will be crucial to develop an anticancer therapy that is undergoing a conversion from a cancer cell-centric strategy to a stroma-centric strategy, more genomically stable.

Keywords: Cancer microenvironment, Breast cancer, Laser capture microdissection, RNA-seq, Cancer progression

Background

Tumors develop by progression through a series of stages. It is now widely accepted that cancer is attributed to the accumulation of genetic alterations in cells. Every cell of the tumor microenvironment is constantly changing in the flow of the cancer progression. The possible role of the tumor microenvironment in neoplastic development has been investigated since the late nineteenth century, with studies published by Stefano Paget in 1989 [1]. The structure and functions of the tumor microenvironment, as well as the relationships with the neoplasia, allow to define more precise prognostic and therapeutic directions.

Breast cancer carcinogenesis is well known, characterized by well defined stages, starting from the atypical ductal hyperplasia progressing to ductal carcinoma in situ (DCIS) and ending, although not necessarily, with the invasive breast cancer (IBC) [2].

In breast cancer, epithelial cells require the stroma to meet their needs of nutrition, waste removal, and structure. It has become clear in recent years that stroma is, indeed, essential for tumor maintenance and growth which can also provide protection from the human immune system attacking the cancer cells [3,
The tumor microenvironment is characterized by an increased number of fibroblasts, expressing alpha-smooth muscle actin, so-called cancer associated fibroblasts (CAFs). Therefore it is important to integrate gene expression changes of both tumoral cells and cancer-associated stroma, occurring during the difference phases of tumor progression. For this reason we focused our attention on a specific kind of breast cancer such as the microinvasive breast carcinoma (MIBC), which is a rare entity in which an invasive component not exceeding 1 mm is found, mostly in a DCIS setting [5]. MIBC accounts for about 5–10% of DCIS with a very good overall prognosis for the patients [6]. The peculiar characteristic of this tumor histotype, that meets our needs, is that we are able to identify on the same tumor section at the meantime all phases of breast cancer progression: normal tissue, DCIS and invasive foci with the respective surrounding stroma.

Formalin-fixed, paraffin-embedded (FFPE) tissue samples stored in diagnostic pathology archives represent an invaluable bio-bank for retrospective clinical research. This interest is primarily driven by the fact that the process of creating FFPE tissue is the most common technique used by clinical and/or research pathologists for tissue processing, evaluation, diagnostics, immunohistochemistry, preservation, and archiviation. The use of FFPE samples in molecular studies presents some great advantages, for example, these types of samples are available and readily accessible in vast quantities, which is a very important element considering a rare disease such as MIBC. The cost associated with their storage is low, as well, and the significant association between pathological and clinical annotations makes FFPE tissue an attractive specimen for biomarker discovery. In particular, thanks to the use of FFPE histological sections, a much higher resolution level is reached, which allows an accurate distinction of tumor areas with specific characteristics that otherwise would not be identifiable.

The aim of the present study is to analyze in MIBC the transcriptome of mammary neoplastic epithelium at different stages of progression together with the respective stroma in order to obtain an overview of the temporal modulation of the gene expression profile during tumor progression enriched by the gene expression profile of the stroma surrounding each tumoral portion at each stage.

Methods

Tissue samples

FFPE blocks from 7 patients diagnosed with MIBC were selected from the Division of Pathology, Pisa University by senior pathologists. Well recognized and approved guidelines of TNM Staging System [7] were used to select the samples. In particular, the identification of the invasive cancer cell portions was performed by immunohistochemistry with p63 [8, 9] in order to identify the absence of myoepithelial cells surrounding nests of carcinoma cells [10].

Laser capture microdissection (LCM) and RNA Extraction

Two mm thick sections were cut from each sample using a new microtome blade for each slide and H&E staining was performed. The PALM RoboMover automatic laser microdissector (Carl Zeiss, Oberkochen, Germany) was used to select the epithelial and stromal cell population. For each sample, seven portions of about 200 cells were microdissected: four related to the breast epithelium and three to the stroma. From the seven tumors we obtained a total of 49 microdissected areas. RNA extraction was performed after an incubation with 50 μl of lysis buffer PKD (Qiagen, Venlo, Netherlands) and 10 μl of proteinase K at 55 °C over night. The automated system Maxwell 16 (Promega, Madison, WI, USA) using the Maxwell® 16 LEV RNA FFPE Purification Kit was used to perform RNA extraction. As expected, RNA concentration was not measurable because of the low amount of material.

The μm² values of the microdissected areas of the seven samples are shown in Table 1.

| Case | NBE (μm²) | CIS (μm²) | IBC (μm²) | EIF (μm²) | S-NBE (μm²) | S-IBC (μm²) | S-EIF (μm²) |
|------|-----------|-----------|-----------|-----------|-------------|-------------|-------------|
| MIBC1 | 139,575   | 165,015   | 93,251    | 190,167   | 146,984     | 190,455     | 126,573     |
| MIBC2 | 97,640    | 140,629   | 83,000    | 123,622   | 154,130     | 97,545      | 95,000      |
| MIBC3 | 198,832   | 247,052   | 126,534   | 187,737   | 187,680     | 101,560     | 196,200     |
| MIBC4 | 172,604   | 186,191   | 182,241   | 192,628   | 194,230     | 116,105     | 154,600     |
| MIBC5 | 152,361   | 195,711   | 68,696    | 98,384    | 155,591     | 61,656      | 83,596      |
| MIBC6 | 165,000   | 321,680   | 95,000    | 166,000   | 198,000     | 125,000     | 182,000     |
| MIBC7 | 171,000   | 246,620   | 101,000   | 98,000    | 201,500     | 80,000      | 170,000     |
cDNA synthesis and amplification
To prepare cDNA from RNA samples, we used the SMARTer Universal Low Input RNA kit (Clontech Laboratories, Takara Bio Inc., Mountain View, CA, USA) that allows high-quality cDNA synthesis starting from as little as 200 pg of input RNA. This kit has been validated for analysis with next-generation sequencing (NGS) instruments to produce NGS-quality cDNA from low concentrations of degraded samples.

Library preparation and sequencing
To prepare the DNA library we used Nextera XT kit (Illumina, San Diego, CA, USA) following the guidelines of the protocol. We load a maximum of six pooling libraries for each cartridge NextSeq High Output (300 cycles) run on a NextSeq 500 instrument (Illumina, San Diego, CA, USA).

Data analysis
The data generated by the NextSeq 500, after converting into fastq format with Bcl2toFastq (version 2.17.1.14; Illumina), were mapped against the reference genome (Hg19) by using STAR aligner (version 2.5.3a). The created bam files were then imported into the SeqMonk (version 1.42.0, Babraham Bionformatics), a tool to enable the visualization and analysis of the mapped sequence data. The data were quantified using the RNA-seq pipeline, included in the previous software, and transformed into log2 format. Data intensity filter, included in SeqMonk, was used to highlight differences in gene expression between different portions. Gene expression patterns of the epithelial and stromal portion at each stage of tumoral progression were compared to each other using SeqMonk, setting, when possible, the threshold of the raw p value at 0.05 and log2fold at >2. Dendrograms and Heatmaps were generated with R (version 3.5.1; pheatmap and dplyr libraries), while SparkLine graphs and tables were created with Excel. Furthermore, to summarize high-dimensional gene expression data we used gene set enrichment analysis (GSEA) [11] which is a common approach to interpreting gene expression data based on the functional annotation of the differentially expressed genes. This is useful for finding out if the differentially expressed genes are associated with a certain biological process or molecular function. We used the GSEA tool combined with the interrogation of different gene sets belonging to the molecular signatures database (MsigDB), in particular: the Kyoto Encyclopedia of Genes and Genomes (KEGG), the Hallmarks and Gene Ontology (GO) gene set databases.

Results

LCM areas
Breast epithelium was chronologically divided into normal breast epithelium (NBE), carcinoma in situ (CIS), emerging invasive fingers (EIF) and invasive breast cancer (IBC) (Fig. 1A–C). For each of the breast epithelium portions we collected the adjacent stroma (S) except for the in situ portion: S-NBE, S-EIF and S-IBC (Fig. 1B, C).

Hierarchical clustering analysis
By deep sequencing of the total RNA, we obtained an average of 24,694,286 reads per sample (ranging from 1,717,350 to 123,193,950) with an average mapping rate of 57% to the reference human genome (hg19). Unsupervised hierarchical clustering analysis generated a dendogram showing a clear distinction between stromal and epithelial samples (Fig. 2a). Moreover in both epithelial and stromal portion the maximum distance, which describes the biggest dissimilarity, is observed, as expected, between the normal and the most advanced stage of cancer progression.

Identification and pathway analysis of the differentially expressed genes (DEGs)
The overall DEGs deriving from the comparisons within the epithelial and stromal portions were used to display a heatmap in which genes were grouped based on their pattern of gene expression. In Fig. 2b, c the data are displayed in a grid where each row represents a gene and each column represents an epithelial or stromal micro-dissected portion. The heatmap was combined with a clustering method which group genes and samples together based on the similarity of their gene expression pattern. It is clear that in both Fig. 2b, c, the epithelial and stromal counterparts localize in a separate branch compared to the tumoral portions.

In Fig. 3a, b the upregulated and downregulated DEGs arising from the different comparisons within the epithelium and stromal groups, are shown. The complete list of DEGs derived from these comparisons are listed in Additional file 1: Table S1.

To understand the biological implications, the overall DEGs were investigated using the GSEA tool supported by several molecular signature databases as reported in the materials and methods section. Several signaling pathways (p < 0.05) emerged interrogating the KEGG database. In Fig. 3c, d the most significant pathways are shown according to their FDR value. The size of each circle reflects number of genes included in the pathway and they are ordered according to its FDR value. The pathways obtained from the DEGs derived from the epithelium portions comparisons exploring the KEGG database are the following: endocytosis, pathways in...
cancer, focal adhesion, ubiquitin mediated proteolysis, cell cycle, fructose and mannose metabolism, regulation of actin cytoskeleton and progesterone-mediated oocyte maturation pathway (Fig. 3c). Equally, the DEGs from stromal portions comparisons, were grouped, according to the KEGG database identifying the following pathways: focal adhesion, regulation of actin cytoskeleton, MAPK signaling pathway, ECM receptor interaction and pathways in cancer (Fig. 3d).

**DEGs obtained from the comparison between tumoral epithelial portions (CIS, EIF, IBC) versus normal epithelial portion (NBE)**

After analyzing the overall DEGs, we focused on the DEGs arising from the single comparison between the normal tissue and each distinct tumoral portions of the progression. In Fig. 4a the Venn diagram describes the comparisons between NBE versus CIS, NBE versus EIF and NBE versus IBC. Twenty-two genes are common for all the intersections. The 22 genes are reported in
Table 2 with the description of each gene and the gene expression value modulation during tumoral progression from NBE to CIS, EIF and eventually to IBC. Interestingly, the MARS gene has a gene expression that gradually increases with tumoral progression, while FAT2 and CWC15 genes show a gradual decrease.

All 22 genes were subjected to the GSEA analysis, and the exploration of the Hallmarks gene-set localizes four of them, PDLIM3, SIAH2, STC2 and KRT15 in the early response to estrogen pathway. While, interrogating...

Fig. 2  
(a) Unsupervised hierarchical clustering made with SeqMonk after transcriptome analysis shows the separation between the stromal and epithelial samples.  
(b, c) overall DEGs of the epithelial and stromal samples respectively were grouped in Heatmaps generated with R software.

Fig. 3  
(a) Upregulated and downregulated DEGs of the epithelium and stromal samples respectively are shown.  
(b) bubble plots showing the most significant pathways in which the DEGs derived from the epithelium portions comparisons are involved on the basis or the FDR value.  
(d) bubble plots showing the most significant pathways in which the DEGs derived from the stromal portions comparisons are involved on the basis or the FDR value. Both the bubble plots were generated with Excel based on the results obtained with GSEA tool combined with the KEGG data set.
the GO gene-set, we observed that three genes, SFRP1, KIF16B and POLR2B are involved in the response to fibroblast growth factor pathway.

**DEGs obtained from the comparison between tumor stromal portions (S-EIF and S-IBC) versus normal stromal portion (S-NBE)**

Comparing the DEGs obtained from the comparison of S-NBE versus S-EIF and S-IBC we identify 32 genes concurrent in all the intersections (Fig. 4b). In Table 3 we report the 32 genes with their description and their gene expression values in the different stages of cancer progression from S-NBE to S-EIF and S-IBC. Focusing on the gene expression modulation associated to the cancer progression, we discovered many genes with a gradual increase of expression from S-NBE to S-EIF and to S-IBC, such as KIAA0368, KIAA1217, STAT2, TRAK1, DDX17, IGF2, HIPK3, AQP1, ACADVL, HSPG2, FLNA, NFE2L1, COL1A1, MXRA5, DYSF, SIN3B, JMJ1D1C and NOTCH2. No gene shows a decreasing downregulation in the progression from S-NBE to S-EIF and S-IBC.

The GSEA tool analysis performed on the 32 genes, revealed, by the Hallmark gene-set, a group of six genes in the epithelial-mesenchymal transition pathway: COL3A1, COL1A1, NOTCH2, COL4A2, FLNA and MXRA5.

Within all stromal portions comparisons, of the 32 genes, three genes were always statistically significant such as NOTCH2, KIAA0368 and NFE2L1, which are shown in Table 4 with the gene description and the fold change expression value. The level of expression for all three genes increases progressively from S-NBE to S-EIF till S-IBC.

**Metabolism pathway analysis: a supervised approach**

Cancer metabolism is one of the oldest areas of research in cancer biology. The issue is based on the concept that metabolic activities are altered in cancer cells compared to normal cells, and that these alterations support the acquisition and maintenance of malignant properties. Because some altered metabolic characteristics are observed quite generally across many types of cancer cells, reprogrammed metabolism is considered a hallmark of cancer [12]. How metabolism is reprogrammed in cancer cells and how to exploit metabolic changes for therapeutic benefit are among the key questions driving research in the field [12]. Guided by this and thanks to the achievement of a solid transcriptome, describing the variations of genes expression occurring in the single compartments of its microenvironment during MIBC tumor progression, we decided to perform a supervised analysis of all gene expression changes of most specific genes involved in cell metabolism. Therefore we analysed gene expression changes through the different tumor microenvironment portions (compared to NBE and S-NBE) during the different phases of cancer progression, as shown in Fig. 5. Data of selected genes are shown in Additional file 1: Table S2 and Additional file 1: Table S3.

**CIS microenvironment (green area in Fig. 5)**

In the CIS we observe a higher expression of hexokinase 1 (HK1) with consequent high levels of glucose-6-phosphate (GLU6P) derived from glucose, with an activation of the pentose phosphate pathway (PPP) (represented by G6PD and PGD genes) and serine pathway (PSAT1 gene) but without an activation of glycolysis (GPI, LDHA genes). Moreover there is a higher expression of genes
linked to ketonic bodies synthesis (HMGCS1 gene), fatty acid synthesis (FASN, ACLY genes) and TCA (tricarboxylic acid) cycle (SDHA, FH genes). We observed, also, an increase in the expression level of MCT4 gene, a carrier that brings the lactate out of the cell. Also the transporter of glutamate (GLU) inside the mitochondrion, SLC25A22 gene, has a higher expression, as a consequence there is a high expression of GLUD2 gene that converts GLU in α-ketoglutarate (α-KG) that enters in TCA cycle. Therefore, in this compartment an oxidative metabolism is detected, with a higher activation of TCA cycle rather than glycolysis.

Table 2 DEGs obtained from the comparison between tumoral epithelial portions (CIS, EIF, IBC) versus normal epithelial portion (NBE) with the respective fold changes values

| Gene ID | Description                    | FC avg-NBE | FC avg-CIS | FC avg-EIF | FC avg-IBC | Trend in tumor progression |
|---------|--------------------------------|------------|------------|------------|------------|--------------------------|
| KRT15   | Keratin 15                     | 1          | 0.10       | 0.13       | 0.29       |                          |
| SFRP1   | Secreted Frizzled Related Protein 1 | 1          | 0.13       | 0.22       | 0.31       |                          |
| IGLL5   | Immunoglobulin Lambda Like Polypeptide 5 | 1          | 0.25       | 0.13       | 0.23       |                          |
| STC2    | Stanniocalcin 2                 | 1          | 0.25       | 0.25       | 0.31       |                          |
| PDLM3   | PDZ And LIM Domain 3            | 1          | 0.18       | 0.06       | 0.23       |                          |
| NRBP1   | Nuclear Receptor Binding Protein 1 | 1          | 27.84      | 31.39      | 21.57      |                          |
| LINCC00342 | Long Intergenic Non-Protein Coding RNA 342 | 1 | 0.22 | 0.07 | 0.12 | |
| FOSB    | FosB Proto-OncoGene, AP-1 Transcription Factor Subunit | 1 | 0.38 | 0.22 | 0.39 | |
| GRSF1   | G-Rich RNA Sequence Binding Factor 1 | 1          | 8.56       | 5.52       | 5.86       |                          |
| MAN2B2  | Mannosidase Alpha Class B Member 2 | 1          | 5.87       | 4.75       | 7.28       |                          |
| NDRG2   | NDRG Family Member 2            | 1          | 0.46       | 0.15       | 0.24       |                          |
| ASB5    | Carbonic Anhydrase 5B           | 1          | 0.16       | 0.15       | 0.21       |                          |
| SIAH2   | Siah E3 Ubiquitin Protein Ligase 2 | 1          | 9.14       | 9.58       | 9.05       |                          |
| GNA15   | G Protein Subunit Alpha 15      | 1          | 0.11       | 0.00       | 0.24       |                          |
| POLR2B  | RNA Polymerase II Subunit B     | 1          | 6.85       | 13.21      | 6.74       |                          |
| KIF16B  | Kinesin Family Member 16B       | 1          | 7.43       | 5.91       | 4.40       |                          |
| ENPP1   | Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 | 1 | 5.87 | 6.64 | 4.13 | |
| FAF2    | Fas Associated Factor Family Member 2 | 1          | 17.09      | 22.70      | 18.74      |                          |
| CWC15   | CWC15 Spliceosome Associated Protein Homolog | 1 | 0.16 | 0.21 | 0.13 | |
| SMARCC2 | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin Subfamily C Member 2 | 1 | 2.40 | 3.12 | 2.15 | |
| FAT2    | FAT Atypical Cadherin 2         | 1          | 0.15       | 0.13       | 0.19       |                          |
| MARS    | Methionyl-tRNA Synthetase        | 1          | 7.30       | 7.86       | 11.27      |                          |

Sparkline graphs with the fold change value for each gene are shown.
### Table 3 DEGs obtained from the comparison between stromal tumor portions (S-EIF and S-IBC) versus normal stromal portion (S-NBE) with the respective fold change values

| Gene ID   | Description                                      | FC avg-SNBE | FC avg-EIF | FC avg-IBC | Trend in tumoral progression |
|-----------|--------------------------------------------------|-------------|------------|------------|------------------------------|
| KIAA0368  | Ecm29 Proteasome Adaptor And Scaffold            | 1           | 708.16     | 2459.01    |                              |
| CANX      | Calnexin                                         | 1           | 17.49      | 15.34      |                              |
| KIAA1217  | KIAA1217                                         | 1           | 70.91      | 193.00     |                              |
| STAT2     | Signal Transducer And Activator Of Transcription 2 | 1           | 256.33     | 424.22     |                              |
| TTC3      | Tetraspeptide Repeat Domain 3                    | 1           | 545.99     | 139.54     |                              |
| COL4A2    | Collagen Type IV Alpha 2 Chain                   | 1           | 65.84      | 62.54      |                              |
| ITM2B     | Integral Membrane Protein 2B                     | 1           | 81.84      | 12.05      |                              |
| YLPM1     | YLP Motif Containing 1                           | 1           | 285.56     | 74.91      |                              |
| TRAK1     | Trafficking Kinesin Protein 1                    | 1           | 218.35     | 358.04     |                              |
| LARP1     | La Ribonucleoprotein Domain Family Member 1      | 1           | 757.56     | 215.51     |                              |
| DDX15     | DEAD-Box Helicase 17                             | 1           | 5.37       | 6.06       |                              |
| KL66      | Kruppel Like Factor 6                            | 1           | 11.55      | 6.46       |                              |
| IGFB2     | Insulin Like Growth Factor 2                     | 1           | 8.31       | 9.43       |                              |
| KIAA0907  | KH Domain Containing 4, Pre-MRNA Splicing Factor  | 1           | 985.15     | 429.54     |                              |
| ANKR217   | Ankryin Repeat Domain 17                         | 1           | 68.24      | 21.19      |                              |
| COL1A1    | Collagen Type III Alpha 1 Chain                  | 1           | 6.14       | 4.03       |                              |
| HPK3      | Homeo-domain Interacting Protein Kinase 3        | 1           | 252.91     | 428.02     |                              |
| LRBP1     | LRR Binding Fli Interacting Protein 1            | 1           | 11.56      | 6.73       |                              |
| AQP1      | Aquaporin 1                                      | 1           | 51.52      | 98.40      |                              |
| ACDVL     | Acyl-CoA Dehydrogenase Very Long Chain           | 1           | 12.44      | 16.97      |                              |
| HSPG2     | Heparan Sulfate Proteoglycan 2                   | 1           | 20.85      | 23.23      |                              |
| SEC31A    | SEC31 Homolog A, COP9 Coat Complex Component      | 1           | 27.73      | 23.74      |                              |
| PTPN18    | Protein Tyrosine Phosphatase, Non-Receptor Type 18 | 1           | 905.73     | 70.86      |                              |
| FLNA      | Filamin A                                        | 1           | 6.41       | 8.04       |                              |
| NF21L1    | Nuclear Factor, Erythroid 2 Like 1               | 1           | 8.81       | 31.84      |                              |
| COL1A1    | Collagen Type I Alpha 1 Chain                    | 1           | 3.17       | 5.91       |                              |
| MKRAS     | Matrix Remodeling Associated 5                   | 1           | 23.40      | 50.14      |                              |
| DYSF      | Dysferlin                                        | 1           | 28.48      | 44.77      |                              |
| SIN3B     | SIN3 Transcription Regulator Family Member 8     | 1           | 9.04       | 62.41      |                              |
| JAK1JUC   | Jumonji Domain Containing 1C                     | 1           | 155.95     | 148.29     |                              |
| C10C      | Complement C1c C Chain                          | 1           | 1304.81    | 858.16     |                              |
| NOTCH2    | Notch 2                                          | 1           | 24.27      | 144.68     |                              |

Sparkline graphs with the fold change value for each gene are shown.
EIF microenvironment (light blue area in Fig. 5)

Also in these cells, glycolysis seems not be appropriately supported; the glucose inside the cells enters in the PPP (G6PD gene). There is a higher expression of the MCT1 gene, the carrier that brings the lactate inside the cell, released by the CIS portion as described above. The fatty acid synthesis is also detected (FASN gene). Besides, as described in the CIS, there is higher expression of SLC25A22 gene and consequent high GLUD2 gene and activation of TCA cycle (SDHA gene). A higher expression (statistically significant) of SLC7A5 gene, the carrier that brings glutamine (GLN) out from the cell, is also detected. A higher expression (statistically significant) of SLC7A5 gene, the carrier that brings glutamine (GLN) out from the cell, is also detected. A higher expression (statistically significant) of SLC7A5 gene, the carrier that brings glutamine (GLN) out from the cell, is also detected. A higher expression (statistically significant) of SLC7A5 gene, the carrier that brings glutamine (GLN) out from the cell, is also detected.
observed. In conclusion, it seems that also this compartment is characterized by an oxidative metabolism.

**S-EIF microenvironment (orange area in Fig. 5)**

In the S-EIF, there is a greater activation of glycolysis (GPI, LDHA genes). There is higher expression of MCT1 gene, carrying the lactate inside the cell and it is converted in PYR (Pyruvate) due to the high expression of lactate dehydrogenase B (LDHB) gene. Moreover we see the activation of the glutaminolysis: a high expression of SLC1A5 gene, the carrier that brings GLN inside the cell, which seems to be released by the EIF portion. Then GLN is converted in α-KG. However, TCA cycle is not very triggered (CS, OGDH, SDHA genes). PPP, fatty acid synthesis and ketonic bodies synthesis are observed. So, in the S-EIF portion, we note a glycolytic metabolism and moreover a higher production of different energy sources (represented by fatty acids and ketonic bodies).

**IBC microenvironment (yellow area in Fig. 5)**

In these cells there is glucose that enters the cell (GLUT1 gene). Also in these cells, like in CIS and EIF, the glucose is not involved so much in glycolysis but in the PPP (G6PD gene) and Serine pathway (PSAT1 gene). Moreover there is a high level of fatty acid synthesis (FASN gene) and ketonic bodies synthesis (HMGCS1 gene). TCA cycle is also detected (SDHA, SL25A22 genes). There is, also, high quantity of lactate entering the cell because of higher expression of the MCT1 gene. Therefore also this compartment shows a type of oxidative metabolism, just like in CIS and EIF compartments.

**S-IBC microenvironment (purple area in Fig. 5)**

The expression of HIF1α gene, responsible of hypoxia, is statistically higher in in this compartment. Glycolysis is activated (GPI gene) and there is higher expression of MCT4 gene, the carrier that brings lactate outside the cell. There is a high overflow of GLN outside the cell, due to high levels of SLC7A5 gene. PPP (PGLS gene), fatty acid synthesis (ACAT1, BDH1 genes) and ketonic bodies synthesis (ACAT1, BDH1 genes) are observed. Instead TCA cycle is not well activated.

**Discussion**

Breast cancer is the most common malignancy and the leading cause of cancer-related death in women worldwide. The microenvironment of these cancers is now recognized as a critical participant in tumor progression. Recent data demonstrate significant gene expression in cells composing the microenvironment during disease progression, which can be explored as biomarkers and targets for therapy. Indeed, gene expression signatures derived from tumor stroma have been linked to clinical outcomes. The tumor microenvironment has assumed a progressively increasing importance over the years; in fact a continuous interaction is observed: on one hand, the tumor is able to influence the microenvironment thanks to extracellular signals, promoting phenomena such as neoangiogenesis and immuno-tolerance; on the other, the cells of the microenvironment favor tumor progression. There is increasing interest in refining our current understanding of the tumor microenvironment. An in-depth study of the tumor microenvironment, can provide information on both the molecular mechanisms underlying the progression as well as on possible etiological factors. In fact, except for some hypotheses of viral etiology [13], we are not yet aware of the etiological cause of breast cancer.

The aim of this study was to analyze the gene expression pattern of microdissected tumoral epithelial cell areas related to each phase of tumoral progression in breast cancer (CIS, EIF and IBC) compared to the normal epithelial cells area (NBE). At the same time we studied also the stromal portions around the tumoral epithelial areas (S-EIF and S-IBC) in comparison to the stromal area surrounding the normal epithelial mammary tissue (S-NBE). We decided to collect these areas, respectively, from 7 patients utilizing the MIBC type, in which cancer progression phases are still very distinguishable. This approach has the advantage of giving a more integral view of the transcriptome changes occurring during cancer progression and allows the investigation of interactions between compartments. The approach can also give insights on the molecular mechanisms that govern cell–cell interactions.

From all gene expression level comparisons, some key aspects have emerged. Focusing on the overall DEGs in epithelial portions, the main pathways in which DEGs were grouped are the endocytosis process, the pathways in cancer and interestingly the fructose and mannose metabolism. Cancer metabolism is essential for the maintenance of cell proliferation in a tumor. The pioneering studies of O. Warburg [14] asserted that a cancer cell needs an increase in glycolysis and a decrease of oxidative metabolism. Nowadays, after several further investigations, the starting concept has been revisited. Metabolism heterogeneity is well known in cancer, both for cancer cells and for the cells of the microenvironment. So a single metabolic program can not be representative of the global metabolism of a tumor. Infact, fructose metabolism, for instance, is different from that of glucose. Through the PPP, fructose induces NADPH and nucleotides synthesis. Besides, glucose also generates
fructose through a specific pathway, the polyol pathway, and some of its metabolites (ex. glycolaldehyde and glyoxal) can affect cell survival [15]. Through this mechanism, this type of metabolism can have a role in neoplastic growth.

The overall DEGs identified in stromal samples, are grouped essentially into the focal adhesion process, the extracellular matrix (ECM) receptor interaction pathway and regulation of actin cytoskeleton pathway. All these processes are linked to cell motility, essential for invasion and for metastasis formation. Cancer cell movement during invasion is a complex system made mainly of membrane protrusions (lamellipodia) arising at the leading edge of migrating cancer cells after activation by extracellular stimuli. Afterwards, the leading membrane is fixed by nascent sites of attachment (focal adhesions) [16]. The F-actin stress fibres contract, creating the tension needed to drag the cell forward, with loss of adhesion at the rear of the cell, so the cell retracts and is dragged in the direction of migration [17]. The involvement, that we detected, of these pathways in the stroma-derived samples is, therefore, perfectly in agreement with the literature, since in our study tumor epithelial cells are progressing towards a real invasion supported by the stromal cells in the process of tumoral progression.

Among all DEGs derived from the comparisons done within tumoral epithelial samples, we identified some key genes that gradually decrease or increase their expression with tumoral progression: KRT15, SFRP1 and MARS. KRT15 (Cytokeratin 15) is a cytoskeletal protein, expressed essentially in the epithelial cells and considered a marker of epithelial stem cells [18]. In our samples we observed a significant decrease of expression in tumoral cells compared to the normal tissue, this is in accordance with Shen et al. in a study on esophageal squamous carcinoma [19] even if in literature there are conflicting results about its role in cancer [20–22]. SFRP1 (Secreted Frizzled Related Protein 1) is a member of SFRP family whose function is to modulate Wnt signaling through direct interaction with Wnts. This gene has already been found involved in breast cancer tumor progression as a tumor suppressor gene and moreover it has been proposed as a target gene for early diagnosis [23]. In our samples SFRP1 expression levels are in complete accordance with the literature, with a decrease during tumoral progression [23]. MARS (Methionyl-tRNA Synthetase) is a member of the class I family of aminoacyl-tRNA synthetases. We found this gene with a gradual increase of expression in tumoral portions, in accordance with the paper of Kim et al. [24] that observed MARS overexpression in non-small cell lung cancer, associated also with a poor prognosis.

The key genes identified among DEGs obtained from the comparisons within the stromal portions are: STAT2, NFE2L1, SIN3B and NOTCH2. All these genes showed a gradual upregulation during the tumoral progression. STAT2 (signal transducer and activator of transcription 2) is a member of STAT family proteins generally involved in response to interferon. In particular STAT2 is a necessary transcription factor in the IFN-α/β signaling pathway [25]. Ogony et al. [26] studied STAT2 in breast cancer cells as a key regulator of the expression of IFITM1 (interferon-induced transmembrane protein 1); together they are involved in the IFNα signaling pathway, in particular their overexpression promote cancer aggressiveness in breast cancer, that agrees with our data. Moreover in literature some papers are already reporting data about IFNa immunotherapy and STAT2 status in melanoma [27] and in other type of diseases [28]. NFE2L1 (nuclear factor, erythroid 2 like 1) is a protein that is involved in globin gene expression in erythrocytes, this protein is not yet well studied, the most important function seems to be related to proteasome process [29]. Very different it is the case of SIN3B (SIN3 transcription regulator family member B), a well known protein that interacts with MYC (MYC proto-oncogene, BHLH transcription factor), which was observed promoting cancer progression and metastasis in breast cancer [30] in accordance with our data. Also NOTCH2 (neurogenic locus notch homolog protein 2) is a very well known protein, that functions as a receptor for membrane-bound ligands jagged-1 (JAG1), jagged-2 (JAG2) and delta-1 (DLL1) to regulate cell-fate determination. Several studies have been conducted on NOTCH2 and cancer, not all in accordance with our results. Some studies describe NOTCH2 as a tumor suppressor gene in breast cancer [31, 32] while as an oncogene in bladder cancer [33] promoting cancer growth and metastasis through epithelial–mesenchymal transition (EMT), which process is fully consistent with our findings. It is important to point out that this is the first time that STAT2, NFE2L1, SIN3B and NOTCH2 genes are described associated to the cancer stroma.

Because of the heterogeneity of cancer cells, each tumor differs in its metabolic status [34]. This is well demonstrated in our samples. In detail, we can deduce that the CIS is a so-called oxidative tumor, because no glycolysis is activated, but there is a great activation of TCA cycle from which the cell receives the energy. This is in accordance with some studies demonstrating that there are tumors, such as the oxidative tumors, where glycolysis is not predominant [35]. Furthermore, we observed in the CIS compartment, a release of lactate from the cell due to an upregulation of the MCT4 gene. We can assume, therefore, that the lactate, released by
CIS, enters in EIF cells, which present an upregulation of the MCT1 gene. EIF cells, which are about to invade, like CIS cells, have a lower activation of glycolysis in favor of the TCA cycle. Also these tumoral cells behave like oxidative tumor cells. Moreover, in the EIF cells, a release of GLN is detected, which enters in the surrounding S-EIF cells and is used as energy fuel, generating GLU through the glutaminolysis. According to our observations, the S-EIF compartment undergo aerobic glycolysis and generate high levels of fuels like fatty acids, lactate, ketonic bodies in compliance to what the reverse Warburg effect describes. It is well known, in fact, that in the reverse Warburg effect, CAFs “feed” the tumoral cells with glycolysis and fatty acid and ketonic bodies synthesis [36, 37]. In turn, cancer cells produce ATP through the TCA cycle and mitochondrial oxidative phosphorylation system (OXPHOS) [38, 39], as we observed in EIF cells. When we focus on the invasion process, the IBC cells show a similar reverse Warburg metabolic situation as in the EIF cells. S-IBC cells are, indeed, characterized by a glycolytic metabolism with release of lactate that enters the IBC tumoral cells, which show an oxidative metabolism.

Conclusions
Our data describe, by the use of LCM on FFPE tissues, the changes of gene expression values during cancer progression in the epithelial cells enriched by the gene expression changes of the surrounding stromal cells. This is the first time that such gene expression values are obtained from FFPE microdissected areas localized on the same tissue section. It is well known that CAFs are necessary for the development and the maintenance of the tumor and particularly for tumor progression. Since we are facing a new phase where there is a conversion from a cancer cell-centric strategy to a stroma-centric strategy, it is crucial to pursue further investigations to better clarify the role of CAFs in tumor progression.

Additional files

Additional file 1. Complete list of DEGs derived from all the comparisons: S-NBE versus S-EIF; S-NBE versus S-IBC and S-NBE versus S-EIF.

Additional file 2. List of observed genes in the epithelial portions involved in the metabolism. The fold change values comparing NBE and tumor portions are reported.

Additional file 3. List of genes observed in the stromal portions involved in the metabolism. The fold change values comparing S-NBE versus S-EIF and S-NBE versus S-IBC are reported.

Abbreviations
DGCS: ductal carcinoma in situ; CAFs: cancer associated fibroblasts; MIBC: microinvasive breast carcinoma; FFPE: formalin-fixed, paraffin-embedded; LCM: laser capture microdissection; NGS: next-generation sequencing; GSEA: gene set enrichment analysis; MsigDB: molecular signatures database; KEGG: Kyoto encyclopedia of genes and genomes; GO: gene ontology; NBE: normal breast epithelium; CIS: carcinoma in situ; EIF: emerging invasive fingers; IBC: invasive breast cancer; S-NBE: stroma-normal breast epithelium; S-EIF: stroma-emerging invasive fingers; S-IBC: stroma-invasive breast cancer; DEGs: differentially expressed genes; HK1: hexokinase 1; GLU6P: glucose-6-phosphate; PPP: pentose phosphate pathway; TCA: tricarboxylic acid; GLU: glutamate; α-KG: α-ketoglutarate; GLN: glutamine; PYR: pyruvate; ECM: extracellular matrix; KRT15: cytokeratin 15; SRP1: secreted frizzled related protein 1; MARS: methionyl-TRNA synthetase; STAT2: signal transducer and activator of transcription 2; IFITM1: interferon-induced transmembrane protein 1; NFE2L1: nuclear factor, erythroid 2 like 1; SIN3B: SIN3 transcription regulator family member B; MYC: MYC proto-oncogene, BHLH transcription factor; NOTCH2: nuclear factor, erythroid 2 like 1; JAG1: jagged-1; JAG2: jagged-2; DLL1: delta-1; OXPHOS: oxidative phosphorylation system.

Acknowledgements
Not applicable.

Authors’ contributions
CMM and AGN ideated and coordinated the project. FL wrote the manuscript, conducted all the experiments and developed the whole project. CS chose all the microinvasive samples, provided all the clinical data and performed the laser capture microdissection. PA performed NGS and all the statistical analysis. SF participated in the experimental designing. NM performed the FFPE sectioning, glass slides preparation and laser capture microdissection. All authors read and approved the final manuscript.

Funding
This work was supported by Fondazione Pisana per la Scienza-ONLUS.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
All patients who participated in this study provided informed consent.

Consent for publication
All patients who participated in this study provided informed consent for data publishing.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Genomic Section, Fondazione Pisana per la Scienza-ONLUS, via Ferruccio Giovannini, 13, S. Giuliano Terme (PI), 56017 Pisa, Italy. 2 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Received: 24 December 2018 Accepted: 24 May 2019
Published online: 03 June 2019

References
1. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8(2):98–101.
2. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973;50(5):1111–8.
3. Bissell MJ, Rizki A, Mian IS. Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol. 2003;15(6):753–62.
4. Matrisian LM, Cunha GR, Mohla S. Epithelial–stromal interactions and tumor progression: meeting summary and future directions. Cancer Res. 2001;61(9):3844–6.
5. Orzáez L, Casella D, Criscenti V, Gjondedaj U, Bianchi S, Vezzosi V, et al. Microinvasive breast cancer: pathological parameters, cancer subtypes distribution, and correlation with axillary lymph nodes invasion. Results of a large single-institution series. Breast Cancer. 2016;23(4):640–8.
6. Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol. 2008;14(2):105–11.

7. Amin MBES, Greene F, Byrd DR, Brookland RK, Washington MK, Gershwenwald JE, Compton CC, Hess KR, et al. AJCC cancer staging manual (8th edition). Berlin: Springer International Publishing: American Joint Commission on Cancer; 2017.

8. Yazhi H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol. 2000;7(2):100–9.

9. Werling RW, Hwang H, Yazhi H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003;27(1):82–90.

10. Damiani S, Ludvikova M, Tomasic G, Bianchi S, Gown AM, Eusebi V. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. An immunocytochemical study. Virchows Arch. 1999;434(3):227–34.

11. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.

12. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

13. Mazzanti CM, Lessi F, Armogida I, Zavaglia K, Franceschi S, Al Hamad M, et al. Human saliva as route of inter-human infection for mouse mammary tumor virus. Oncotarget. 2015;6(21):18355–63.

14. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–30.

15. Charrez B, Qiao L, Hebbard L. The role of fructose in metabolism and cancer. Horm Mol Biol Clin Investig. 2015;22(12):2981–92.

16. Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol. 2007;9(10):1110–21.

17. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.

18. Nakamura Y, Nakamura T, Fujii K, et al. The possible correlation of Notch-1 and p63 expression with the diagnosis of ductal carcinoma in situ. Histol Histopathol. 2002;17(7):949–59.

19. Cellis JE, Gromova I, Cabezon T, Gromov P, Shen T, Timmermans-Wielenga V, et al. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: a relationship between CK15+ progenitor/ amplified cells and pre-malignant lesions and invasive disease. Mol Oncol. 2007;1(3):321–49.

20. Kothari C, Ouellette G, Labrie Y, Jacob S, Diorio C, Durocher F. Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy. Oncotarget. 2018;9(100):37407–20.

21. Kim EY, Jung JY, Kim A, Kim K, Chang YS. Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer. BMC Cancer. 2017;17(1):467.

22. Leung S, Qureshi SA, Kerr IM, Darnell JE Jr, Stark GR. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol. 1995;15(3):1312–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.